EAU 2017 - Renal Cancer

EAU 2017: Parenchyma volume and renal function after different types of nephron-sparing minimally invasive surgery in patients with renal cell carcinoma

London, England (UroToday.com) In this session, the group from N. N. Petrov Research Institute of Oncology described differences in renal functional results after various forms of nephron-sparing surgery.

EAU 2017: Lymph node dissection is not associated with increased 30-day complication among patients undergoing radical nephrectomy for renal cell carcinoma: a propensity-score based analysis

London, England (UroToday.com) The role of lymph node dissection (LND) at the time of radical nephrectomy (RN) is controversial because its oncologic benefit is unclear. Notably, there is little information on complication rates associated with LND to inform clinical risk-benefit analyses.

EAU 2017: Should partial nephrectomy be considered an imperative indication in stage II chronic kidney disease?

London, England (UroToday.com) At present, partial nephrectomy (PN) is strongly indicated in patients with stage III or worse (GFR < 60) chronic kidney disease (CKD). However, PN remains a relative indication for patients with stage II CKD (GFR 60-89). The authors compared renal functional and survival outcomes for patients with baseline stage II CKD who underwent PN or radical nephrectomy (RN).

EAU 2017: State-of-the-art Lecture Immunotherapy: Open Questions and Trials

London, England (UroToday.com) At this morning’s EAU 2017 thematic session on Immuno-oncology, Dr. Laurence Albiges provided a very educational presentation on current open questions and trials ongoing in the immune therapy setting for renal cell carcinoma. Dr. Albiges started her talk by delineating first, second and third line treatment and making the argument that fourth line treatment should focus on drugs not previously given, especially nivolumab or cabozantinib.

State-of-the-art Lecture Immunotherapy: Impact from Surgeon’s Point of View

London, England (UroToday.com) Dr. von Rundstedt provided the surgeon’s point of view regarding immune therapy at this morning’s EAU 2017 thematic session on Immuno-oncology. As Dr. von Rundstedt aptly and humorously described “Immune therapy for surgeons is kind of like Mary Poppins: we did not expect to see her, she is full of surprises, we don’t know what to think of her, we may not always understand her, and she uses strange names!”

EAU 2017: State-of-the-art Lecture Immunotherapy: Impact from Oncologist’s Point of View

London, England (UroToday.com) This morning’s thematic session on Immuno-oncology for Renal and Urothelial Cancer at the EAU 2017 Annual Congress was highly anticipated given the many exciting studies that have been published in the last number of months. Dr. Thomas Powles from London began the session by giving the medical oncologist’s viewpoint, specifically with regards to renal cancer.

EAU 2017: Debate on Kidney Cancer – partial nephrectomy is better done with the robot - Con

London, England (UroToday.com) In this session, Dr. Van Poppel elucidated the places where partial nephrectomy should be done open. Despite no overall survival benefit in his own trial (EORTC) favoring partial nephrectomy over radical nephrectomy in masses less than 5 cm, Dr. Van Poppel acquiesced that we should be doing partial nephrectomy because it is in the guidelines. He focused the talk on oncologic cure, preservation of renal function, and complications.

Page 1 of 2

EAU 2017 - Renal Cancer

Free Daily and Weekly newsletters offered by content of interest

Login